Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Non Operating Income (2022 - 2025)

Vivos Therapeutics has reported Non Operating Income over the past 4 years, most recently at -$631000.0 for Q4 2025.

  • Quarterly Non Operating Income fell 827.94% to -$631000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.5 million through Dec 2025, down 1255.05% year-over-year, with the annual reading at -$1.5 million for FY2025, 1246.36% down from the prior year.
  • Non Operating Income was -$631000.0 for Q4 2025 at Vivos Therapeutics, up from -$679000.0 in the prior quarter.
  • Over five years, Non Operating Income peaked at $51000.0 in Q1 2023 and troughed at -$679000.0 in Q3 2025.
  • The 4-year median for Non Operating Income is -$37500.0 (2022), against an average of -$123500.0.
  • Year-over-year, Non Operating Income surged 234.21% in 2023 and then plummeted 3672.22% in 2025.
  • A 4-year view of Non Operating Income shows it stood at -$38000.0 in 2022, then surged by 63.16% to -$14000.0 in 2023, then crashed by 385.71% to -$68000.0 in 2024, then tumbled by 827.94% to -$631000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Non Operating Income are -$631000.0 (Q4 2025), -$679000.0 (Q3 2025), and -$163000.0 (Q2 2025).